Stockpolly
Search
Delisting risk
HCWB · NASDAQ · Biotechnology

HCW Biologics (HCWB)

Develops fusion immunotherapies and cell-therapy manufacturing reagents.

$3.35
Pre-market+0.03 (+0.78%)
At close$3.32(−3.77%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue111100000070
Cost of revenue161000000000
Gross profit0−51000000070
5681543233333
Research & development222211111111
4461232022222
Selling & marketing000000000000
General & administrative4461232022222
Other expenses000101000000
Operating income−5−11−7−15−4−3−2−3−3−33−3
00000002−141−2
Interest income000000000000
Interest expense000000000000
Other non-operating income00000−10−21−402
Income before tax−5−11−7−15−4−3−2−2−514−5
Income tax expense000000000000
Net income from continuing operations−5−11−7−15−4−3−2−2−514−5
Net income−5−11−7−15−4−3−2−2−514−5
EPS, basic−$0.14−$1.80−$1.20−$2.40−$0.60−$0.52−$0.30−$40.74−$12.12−$9.90$11.82−$43.97
EPS, diluted−$0.14−$1.80−$1.20−$2.40−$0.60−$0.52−$0.30−$40.74−$12.12−$9.90$11.82−$43.97
Weighted average shares, basic3666666700000
Weighted average shares, diluted3666666700000
EBITDA−5−10−7−15−4−2−1−1−414−5
Depreciation & amortization000001000000
EBIT−5−11−7−15−4−3−2−2−414−5